Recursion Pharmaceuticals
RXRX
$3.31
-0.90%
Recursion Pharmaceuticals is a clinical-stage biotechnology company that integrates technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It operates as a distinct player in the AI-driven drug discovery space, leveraging a proprietary platform to decode biology and identify novel therapeutic candidates. The current investor narrative centers on the potential of its AI platform to transform drug development, though the stock has faced significant volatility amid skepticism about its unproven approach and near-term losses, as highlighted in recent comparisons to more established players like Moderna.…
RXRX
Recursion Pharmaceuticals
$3.31
Related headlines
Investment Opinion: Should I buy RXRX Today?
Rating: Hold. The thesis is that RXRX offers a speculative bet on AI-driven drug discovery, but the lack of commercial validation and high cash burn warrant caution. Analyst consensus is limited, with only 2 analysts providing estimates, and no clear buy/hold/sell distribution. The average revenue estimate of $247.5 million implies significant growth, but the wide range reflects high uncertainty.
Supporting Evidence: The PS ratio of 24.5x is elevated relative to the biotech industry average of 5-10x, indicating a premium for the AI platform. Revenue is estimated at $247.5 million, but the company has negative net margin of -863% and negative operating margin of -868%. Free cash flow is negative, as shown by a PCF ratio of -4.92x. The stock trades at $3.56, near the 52-week low of $2.77, offering limited downside protection. The lack of analyst target prices makes it difficult to assess upside potential.
Risks & Conditions: The biggest risks are failure to achieve revenue estimates, continued cash burn leading to dilution, and competitive pressure from established biotech firms. This Hold would upgrade to Buy if the company demonstrates a clear path to profitability (e.g., positive operating margin) or if revenue exceeds $300 million. It would downgrade to Sell if cash burn accelerates or if clinical trial results are negative. Overall, RXRX appears overvalued relative to its current financials but fairly valued if the revenue estimates are achieved.
Sign up to view all
RXRX 12-Month Price Forecast
The AI assessment is bearish due to the company's extreme unprofitability, premium valuation, and sustained downtrend. While the AI platform has potential, the lack of commercial validation and high cash burn present significant risks. The base case of modest revenue growth is already priced in, but any disappointment could lead to severe downside. An upgrade to neutral would require evidence of improving margins or a major partnership.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Recursion Pharmaceuticals's 12-month outlook, with a consensus price target around $4.30 and implied upside of +29.9% versus the current price.
Average Target
$4.30
2 analysts
Implied Upside
+29.9%
vs. current price
Analyst Count
2
covering this stock
Price Range
$3 - $4
Analyst target range
Only 2 analysts cover RXRX, with a consensus estimated EPS of -$0.94 and revenue of $247.5 million. The lack of buy/hold/sell distribution and target prices indicates insufficient coverage. The wide range of EPS estimates (-$1.38 to -$0.34) and revenue estimates ($125.8M to $337.2M) reflects high uncertainty. Limited analyst coverage typically leads to higher volatility and less efficient price discovery, as seen in the stock's large price swings.
Bulls vs Bears: RXRX Investment Factors
Recursion Pharmaceuticals presents a high-risk, high-reward investment case. On the bull side, the AI platform could revolutionize drug discovery, supported by a strong balance sheet and Cathie Wood's backing. However, the bear case is compelling: extreme losses, a premium valuation, limited analyst coverage, and a sustained downtrend. The single most important tension is whether the company can translate its AI platform into tangible revenue and path to profitability. If it does, the stock could re-rate significantly; if not, further downside is likely. Currently, the bearish evidence is stronger due to the lack of commercial validation and high cash burn.
Bullish
- AI Platform Potential: Recursion's proprietary AI-driven drug discovery platform aims to industrialize the process, potentially reducing time and cost. This disruptive approach could capture significant market share if validated, as evidenced by the company's high PS ratio of 24.5x, reflecting investor optimism.
- Revenue Growth Trajectory: Estimated revenue for the current fiscal year is $247.5 million, implying substantial growth from minimal historical revenue. If realized, this would demonstrate commercial progress and support the platform's value proposition.
- Strong Balance Sheet: The company has a current ratio of 5.5 and a debt-to-equity ratio of 0.07, indicating ample liquidity and minimal leverage. This financial stability provides a runway for continued R&D investment without near-term solvency risk.
- Cathie Wood's Endorsement: ARK Invest, led by Cathie Wood, has been buying RXRX shares, signaling conviction in the company's long-term disruptive potential. Wood's track record with innovative tech stocks adds credibility to the bull case.
Bearish
- Negative Net Margin: The net margin is -863%, reflecting deep losses as the company is pre-revenue or has minimal revenue. This extreme unprofitability raises concerns about the path to profitability and cash burn rate.
- High Valuation vs. Peers: With a PS ratio of 24.5x, RXRX trades at a significant premium to the biotech industry average of 5-10x for pre-revenue companies. This implies high expectations that may not be met, leading to potential multiple compression.
- Limited Analyst Coverage: Only 2 analysts cover the stock, with a wide range of EPS estimates (-$1.38 to -$0.34) and revenue estimates ($125.8M to $337.2M). This lack of consensus indicates high uncertainty and inefficient price discovery.
- Sustained Price Downtrend: The stock is down 37.7% over the past year and trades near the bottom of its 52-week range ($2.77-$7.18). The persistent weakness suggests market skepticism about the company's near-term prospects.
RXRX Technical Analysis
The stock is in a sustained downtrend over the past year, with a 1-year price change of -37.7%. The current price of $3.56 sits at 18.5% of its 52-week range ($2.77 low to $7.18 high), indicating it is near the lower end of the range, which could suggest a value opportunity but also reflects persistent weakness. The 52-week low of $2.77 was set in late March 2026, and the stock has since recovered but remains far from the high.
Beta
0.99
0.99x market volatility
Max Drawdown
-58.2%
Largest decline past year
52-Week Range
$3-$7
Price range past year
Annual Return
-36.6%
Cumulative gain past year
| Period | RXRX Return | S&P 500 |
|---|---|---|
| 1m | +0.6% | +0.0% |
| 3m | -8.1% | +7.6% |
| 6m | -29.1% | +9.1% |
| 1y | -36.6% | +21.3% |
| ytd | -21.2% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RXRX Fundamental Analysis
Revenue data is not available in the provided financials, but the company is pre-revenue or has minimal revenue, with a PS ratio of 24.5x and negative net margin of -863%. The most recent quarterly revenue is not disclosed, but the estimated revenue for the current fiscal year is $247.5 million, implying a significant growth trajectory if realized. However, the lack of historical revenue data makes it difficult to assess the growth trend.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RXRX Overvalued?
Since net income is negative (EPS of -$0.35), the PE ratio is not meaningful, so we use the PS ratio of 24.5x. The forward PE is -3.78x, indicating continued losses. The PS ratio is high relative to the industry average for biotechnology (typically 5-10x for pre-revenue companies), suggesting a premium for the AI platform. The PEG ratio of 0.19x is based on estimated EPS growth, but negative earnings make this metric unreliable.
PE
-2.8x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-2.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Recursion's most pressing financial risk is its extreme unprofitability, with a net margin of -863% and negative operating margin of -868%. The company burns cash rapidly, as indicated by a negative PCF ratio of -4.92x. With estimated revenue of $247.5 million but no disclosed historical revenue, the path to profitability is uncertain. The high PS ratio of 24.5x implies that the market is pricing in significant future growth, which may not materialize, leading to potential valuation collapse. Additionally, the company's reliance on continued funding (debt-to-equity of 0.07 is low, but cash burn could necessitate dilution) adds financial risk.
Market & Competitive Risks: RXRX trades at a premium valuation relative to biotech peers, making it vulnerable to multiple compression if growth disappoints. The stock's beta of 0.995 indicates market-like volatility, but its 1-year price decline of 37.7% versus the S&P 500's gain of 20.6% shows severe underperformance. Competitive risk is high as larger players like Moderna have proven platforms and diversified pipelines. Regulatory risk is also present, as any setback in clinical trials could devastate the stock. Recent news comparing RXRX unfavorably to Moderna highlights the competitive headwinds.
Worst-Case Scenario: In a worst-case scenario, the company fails to achieve revenue targets, cash burn accelerates, and the stock falls to its 52-week low of $2.77, representing a 22% decline from the current price of $3.56. If clinical trials fail or the platform is discredited, the stock could drop further, potentially to $2.00 or below, implying a loss of over 40%. The historical max drawdown of -58.17% suggests that such a decline is within the realm of possibility.
FAQ
The key risks include: 1) Financial risk: extreme losses with a net margin of -863% and negative free cash flow (PCF ratio -4.92x), which could lead to dilution. 2) Valuation risk: a PS ratio of 24.5x leaves little room for error; any disappointment could cause multiple compression. 3) Competitive risk: larger players like Moderna have proven platforms. 4) Company-specific risk: the AI platform is unproven, and clinical trial failures could devastate the stock. The most severe risk is a failure to achieve revenue estimates, which could push the stock below $2.77.
The 12-month forecast is uncertain due to limited analyst coverage. In the bull case (20% probability), the stock could reach $5.00-$7.18 if revenue exceeds $300 million and clinical trials succeed. The base case (50% probability) sees the stock trading between $3.00 and $4.50 as revenue meets estimates. The bear case (30% probability) could see the stock fall to $2.00-$2.77 if revenue disappoints. The most likely scenario is the base case, assuming revenue of $247.5 million is achieved.
RXRX appears overvalued based on traditional metrics. Its PS ratio of 24.5x is significantly higher than the biotech industry average of 5-10x for pre-revenue companies, implying the market is pricing in substantial future growth. However, the company has negative earnings and margins, making the PE ratio meaningless. The PEG ratio of 0.19x is unreliable due to negative earnings. Compared to its own history, the stock is near its 52-week low, suggesting it may be undervalued relative to its recent past, but the high PS ratio indicates it is still expensive relative to fundamentals.
RXRX is a high-risk, high-reward stock that may appeal to speculative investors. The company has a strong balance sheet with a current ratio of 5.5 and low debt, but it is deeply unprofitable with a net margin of -863%. The stock trades near its 52-week low of $2.77, offering potential upside if the AI platform succeeds, but the lack of analyst coverage and wide estimate ranges indicate high uncertainty. For risk-averse investors, it is not a good buy; for those with high risk tolerance and a long-term view, it could be a small portfolio position.
RXRX is more suitable for long-term investment due to its speculative nature and high volatility. The stock has a beta of 0.995, similar to the market, but its 1-year decline of 37.7% shows significant downside risk. Short-term trading is risky given the lack of catalysts and low liquidity (short ratio of 8.63 days). A long-term horizon of 3-5 years is recommended to allow the AI platform to potentially generate revenue and profits. The company pays no dividend, so total return depends on price appreciation.